Physician profile
Gary Mirkin
NPI 1982664421
$1,909.76
in general payments reported to CMS, 2019-2025
21 companies · $371 in 2025
The $371 reported for 2025 was more than what 89% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $172 · 2020: $225 · 2021: $315 · 2022: $257 · 2023: $173 · 2024: $398 · 2025: $371.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $942.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $941.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $314.55 | 2021-2025 | Penmenvy, Bexsero |
| Merck Sharp & Dohme LLC | $257.90 | 2019-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Kaleo, INC. | $229.91 | 2020-2024 | Auvi-Q |
| Pfizer INC. | $174.27 | 2019-2024 | |
| Cranial Technologies, INC | $160.13 | 2020-2025 | Doc Band |
| Sanofi Pasteur INC. | $157.52 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $127.64 | 2024 | |
| Cognoa, INC. | $68.35 | 2021-2022 | |
| Alk-Abello, INC | $54.05 | 2024 | Grastek, Ragwitek, Odactra |
| Seqirus USA INC | $45.04 | 2023-2025 | Flucelvax, Flucelvax Quadrivalent |
| Shire North American Group INC | $40.38 | 2019 | |
| Sobi, INC | $40.27 | 2019-2021 | |
| Genentech USA, INC. | $37.82 | 2019-2020 | |
| Tris Pharma INC | $35.03 | 2020 | |
| Genzyme Corporation | $33.50 | 2025 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aytu Biopharma, INC. | $28.41 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $24.84 | 2025 | Vpriv |
| Vertical Pharmaceuticals, LLC | $21.43 | 2019 | |
| Corium, LLC | $20.80 | 2022 | |
| Meridian Bioscience INC. | $19.11 | 2020 | |
| Astrazeneca Pharmaceuticals Lp | $18.81 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Mirkin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.